Back to Search
Start Over
Thrombocytopenia associated with clonidine in a case of clozapine-induced sialorrhea
- Source :
- The Mental Health Clinician
- Publication Year :
- 2020
- Publisher :
- College of Psychiatric and Neurologic Pharmacists (CPNP), 2020.
-
Abstract
- Clozapine is approved by the US Food and Drug Administration for treatment-resistant schizophrenia and mitigation of suicidality in patients with schizophrenia or schizoaffective disorder. Clozapine requires monitoring of adverse events, such as hypotension, myocarditis, cardiomyopathy, seizures, severe neutropenia, and gastrointestinal hypomotility. Sialorrhea is another adverse event that can be bothersome for patients and result in nonadherence or the development of aspiration pneumonia. Clonidine, an α2A adrenergic receptor agonist, is one medication option that can reduce or eliminate sialorrhea. Clonidine is generally well tolerated but can contribute to hypotension and sedation. One adverse event associated with clonidine not described in the literature is thrombocytopenia. Reported is a case of clonidine-associated thrombocytopenia when used for the treatment of clozapine-induced sialorrhea.
- Subjects :
- drug safety
Sedation
thrombocytopenia
Schizoaffective disorder
Case Reports
Aspiration pneumonia
03 medical and health sciences
0302 clinical medicine
medicine
Pharmacology (medical)
General Pharmacology, Toxicology and Pharmaceutics
sialorrhea
clonidine
Adverse effect
Clozapine
Sialorrhea
clozapine
business.industry
medicine.disease
030227 psychiatry
Clonidine
Neuropsychology and Physiological Psychology
Schizophrenia
Anesthesia
Neurology (clinical)
medicine.symptom
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- ISSN :
- 21689709
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- Mental Health Clinician
- Accession number :
- edsair.doi.dedup.....a2e238261211376bbae0000cb1f87686